HC Wainwright & Co. Reinstates Buy on Corbus Pharmaceuticals, Announces $80 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reinstated a Buy rating on Corbus Pharmaceuticals (NASDAQ:CRBP) with an $80 price target, as announced by analyst Andrew Fein.
July 22, 2024 | 10:31 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reinstated a Buy rating on Corbus Pharmaceuticals (NASDAQ:CRBP) with an $80 price target, as announced by analyst Andrew Fein.
The reinstatement of a Buy rating and a high price target of $80 by a reputable analyst is likely to positively impact the stock price of Corbus Pharmaceuticals in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100